Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)

Mead Johnson Nutrition

Status

Not yet enrolling

Conditions

Growth

Treatments

Other: Extensively hydrolyzed casein formula (C-eHCF), commercially available

Other: Extensively hydrolyzed casein formula (INV-eHCF)

Study type

Interventional

Funder types

Industry

Identifiers

NCT07513506

3397-2

Details and patient eligibility

About

This is a research study to compare an investigational infant formula against a currently marketed infant formula. An investigational infant formula is one that has never been approved by the United States Food and Drug Administration (FDA).

The purpose of this research study is to evaluate the growth and tolerance of infants who consume a new (not yet available to buy) extensively hydrolyzed cow milk protein infant formula compared to an extensively hydrolyzed cow milk protein infant formula that is currently available to buy. The study will also look at the growth of your baby, how many poops your baby has, what the poops are like (for example, soft or hard), how much study formula your baby drinks, how well your baby handles the study formula (such as spit-up, fussiness, gas, colic, or changes in sleep), and any health problems that might come up during the study.

Full description

The current study is designed to demonstrate that an investigational extensively hydrolyzed casein formula developed utilizing a new manufacturing process, is well-accepted, tolerated and supports typical growth similar to a control extensively hydrolyzed casein formula in term, healthy infants from approximately 14 to 126 days of age. This formula has been determined to have a high-quality protein similar to that of intact casein, as seen in the protein efficiency ratio (PER) study. Secondary objectives will include tolerance, intake and stool characteristics between infants assigned to receive the control or the investigational formula through approximately 126 days of age. Control and investigational formulas have the same nutritional composition per 100 kcal.

Enrollment

214 estimated patients

Sex

All

Ages

10 to 14 days old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

10 to 14 days of age at randomization, inclusive (day of birth is considered Day 0)
Singleton birth
Gestational age of 37 weeks + 0 days to 41 weeks + 6 days, inclusive
Birth weight of 2500 g to 4200 g, inclusive
Birth weight appropriate for gestational age (AGA, defined as birth weight-for-age between 10th and 90th percentile, inclusive)
Exclusively receiving infant formula for at least 24 hours prior to randomization
Parent(s) or legal guardian(s) have full intention to exclusively feed their infant study formula through 126 days of age
Signed informed consent obtained from parent or legal guardian for infant's participation in the study
Signed authorization obtained from parent or legal guardian to use and/or disclose Protected Health Information for the infant from birth through the length of the study period
Parent or legal guardian agrees not to enroll the infant in another interventional clinical study while participating in this study
Decentralized participant's parent/caregiver or legal guardian has access to reliable internet and technology for remote visits.
Decentralized participant's parent/caregiver or legal guardian anticipates having a second adult available for all remote visits.

Exclusion criteria

History of underlying metabolic or chronic disease; congenital malformation; immunodeficiency, gastrointestinal condition, or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the infant to ingest food by mouth, the normal growth and development of the infant, or the evaluation of the infant
Evidence of feeding difficulties or history of formula intolerance, such as vomiting or poor intake at time of randomization
First degree relative (if known) history of cow's milk protein intolerance or allergy
Maternal history with known adverse effects on the fetus and/or newborn infant in the opinion of the investigator, such as, but not limited to diabetes, smoking, active tuberculosis, perinatal infection, or substance abuse
Weight at Visit 1 is <98% of birth weight [weight at Visit 1÷ birth weight) x 100< 98%]
Infants whose parent, legal guardian, or first-degree relative is an employee of MJN/Reckitt or an affiliated vendor (e.g., CRO, laboratory, or data management provider) involved in the clinical trial, and who is directly or indirectly engaged in the design, conduct, oversight, or analysis of the study; has access to confidential study information; or holds supervisory authority over personnel involved in the study.